Atria Investments Inc Acquires 12,430 Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST)

Atria Investments Inc boosted its holdings in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 44.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 40,421 shares of the company’s stock after buying an additional 12,430 shares during the period. Atria Investments Inc owned approximately 0.08% of Milestone Pharmaceuticals worth $61,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. BNP Paribas Financial Markets increased its stake in Milestone Pharmaceuticals by 177.0% during the first quarter. BNP Paribas Financial Markets now owns 16,900 shares of the company’s stock valued at $30,000 after acquiring an additional 10,800 shares during the period. Lion Point Capital LP grew its holdings in shares of Milestone Pharmaceuticals by 1.7% during the 2nd quarter. Lion Point Capital LP now owns 2,340,207 shares of the company’s stock worth $3,089,000 after purchasing an additional 40,000 shares in the last quarter. Finally, Valeo Financial Advisors LLC grew its holdings in shares of Milestone Pharmaceuticals by 100.0% during the 3rd quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock worth $30,000 after purchasing an additional 10,000 shares in the last quarter. 86.18% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Rodman & Renshaw started coverage on Milestone Pharmaceuticals in a research report on Thursday, August 22nd. They issued a “buy” rating and a $9.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of Milestone Pharmaceuticals in a research note on Monday, October 14th.

Milestone Pharmaceuticals Trading Down 0.5 %

MIST stock opened at $1.84 on Monday. The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 2.18. The firm has a market cap of $98.12 million, a P/E ratio of -2.27 and a beta of 1.72. Milestone Pharmaceuticals Inc. has a 1-year low of $1.12 and a 1-year high of $3.52. The business’s 50 day moving average is $1.58 and its 200-day moving average is $1.52.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. Equities analysts anticipate that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current fiscal year.

Milestone Pharmaceuticals Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.